html[data-identity='g1'] .g1-header .g1-header-wide .g1-header-layers button { display: none; } html[data-identity='g1'] .g1-header-wide .g1-header-layers a { align-self: center; } html[data-identity='g1'] .g1-header .g1-header-narrow { display: none; } html[data-identity='g1'] .g1-header-nojs { display: none; } @media (width < 721px) { html[data-identity='g1'] .g1-header .g1-header-nojs { display: flex; flex-wrap: wrap; column-gap: 20px; padding: 0 16px 8px; } html[data-identity='g1'] .g1-header-nojs ul { display: flex; gap: 20px; list-style: none; margin: 0; padding: 0; box-shadow: none; } html[data-identity='g1'] .g1-header-nojs a { display: block; padding: 6px 0; font-size: 15px; line-height: 24px; color: var(--ink2); text-decoration: none; } html[data-identity='g1'] .g1-header-nojs a[aria-current='true'] { color: var(--ink); text-decoration: underline 2px var(--ember); text-underline-offset: 6px; } }

Allium sativumFinding

Allium sativum has no detected effect on C-reactive protein concentration

no difference foundLimited evidenceFinding

01 · The sentence it was drawn from

“There were no significant differences in the lipid profile, BMI or CRP between the AGE and the placebo groups.”

Quoted verbatim from The effect of aged garlic extract on the atherosclerotic process - a randomized double-blind placebo-controlled trial.

This finding among the 114 findings on its endpoint

Allium sativum

C-reactive protein concentration

no difference found

Who: Asymptomatic adults aged 40 to 75 with Framingham risk score 10 or more and a positive coronary artery calcium score, most on antihypertensive or lipid-lowering medication; whole randomised population at 12 months
Dose studied: 2400 mg aged garlic extract daily (two 600 mg capsules twice daily), 12 months

Limited evidencePMID 32349742 · 2020

02 · The study

Study: RCT
Duration: 12 months

Evidence, by strength

strong
moderate
limitedthis finding
very limited
insufficient

03 · The paper

BMC complementary medicine and therapies

The effect of aged garlic extract on the atherosclerotic process - a randomized double-blind placebo-controlled trial.

2020PMID 32349742doi 10.1186/s12906-020-02932-5Industry funded

What else it reported1 finding · 0 compounds · 1 endpoint

04 · To cite this finding

This address does not change

https://catalystproject.ai/e/01M71HT0YRZ06CNHB8QFPHCVMG